Experimental cell therapy targets hard-to-treat ovarian cancers
NCT ID NCT06342986
First seen Nov 01, 2025 · Last updated May 22, 2026 · Updated 29 times
Summary
This early-phase trial tests a new treatment called FT536 for people with ovarian, fallopian tube, or primary peritoneal cancer that has come back. The treatment is given directly into the belly three times in one week, after a short course of chemotherapy to prepare the body. Only 3 people took part, and the goal was to see if the treatment is safe and how long it keeps the cancer from growing.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
University of Minnesota Masonic Cancer Center
Minneapolis, Minnesota, 55455, United States
Conditions
Explore the condition pages connected to this study.